<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cardiol Therapeutics Inc Class A — News on 6ix</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a</link>
<description>Latest news and press releases for Cardiol Therapeutics Inc Class A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:27:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cardiol-therapeutics-inc-class-a" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835f81a78dffbe2df130581.webp</url>
<title>Cardiol Therapeutics Inc Class A</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a</link>
</image>
<item>
<title>Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-expands-us-maveric-phase-iii-trial-network-to-address-growing-interest-in-the-pivotal-program</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-expands-us-maveric-phase-iii-trial-network-to-address-growing-interest-in-the-pivotal-program</guid>
<pubDate>Tue, 28 Apr 2026 11:27:00 GMT</pubDate>
<description>Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in ...</description>
</item>
<item>
<title>Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-highlight-maveric-phase-iii-trial-and-recently-published-archer-results-in-live-interview-with-barchart</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-highlight-maveric-phase-iii-trial-and-recently-published-archer-results-in-live-interview-with-barchart</guid>
<pubDate>Tue, 14 Apr 2026 11:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (...</description>
</item>
<item>
<title>Cardiol Therapeutics Announces Year-End 2025 Update on Operations</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-year-end-2025-update-on-operations-2</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-year-end-2025-update-on-operations-2</guid>
<pubDate>Wed, 01 Apr 2026 11:27:00 GMT</pubDate>
<description>Initiated pivotal Phase III MAVERIC trial of CardiolRx&#x2122; in recurrent pericarditis and surp...</description>
</item>
<item>
<title>Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-present-at-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-present-at-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 12:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the...</description>
</item>
<item>
<title>Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-archer-phase-ii-122700812</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-archer-phase-ii-122700812</guid>
<pubDate>Tue, 10 Feb 2026 12:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.The peer-reviewed article reports results from a randomized, double-blind,..</description>
</item>
<item>
<title>Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-closing-of-bought-deal-financing-and-full-exercise-of-over-allotment-option-for-gross-proceeds-of-dollar1485-million</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-closing-of-bought-deal-financing-and-full-exercise-of-over-allotment-option-for-gross-proceeds-of-dollar1485-million</guid>
<pubDate>Fri, 23 Jan 2026 14:16:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...</description>
</item>
<item>
<title>Canadian Investment Regulatory Organization Trade Resumption - CRDL</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/canadian-investment-regulatory-organization-trade-resumption-crdl</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/canadian-investment-regulatory-organization-trade-resumption-crdl</guid>
<pubDate>Fri, 16 Jan 2026 13:53:00 GMT</pubDate>
<description>Canadian Investment Regulatory Organization Trade Resumption - CRDL Canada NewsWire ...</description>
</item>
<item>
<title>Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-bought-deal-financing-for-gross-proceeds-of-dollar135-million</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-bought-deal-financing-for-gross-proceeds-of-dollar135-million</guid>
<pubDate>Fri, 16 Jan 2026 13:46:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...</description>
</item>
<item>
<title>Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-inc-announces-bought-deal-financing-for-gross-proceeds-of-dollar135-million</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-inc-announces-bought-deal-financing-for-gross-proceeds-of-dollar135-million</guid>
<pubDate>Fri, 16 Jan 2026 13:42:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...</description>
</item>
<item>
<title>Canadian Investment Regulatory Organization Trading Halt - CRDL</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/canadian-investment-regulatory-organization-trading-halt-crdl</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/canadian-investment-regulatory-organization-trading-halt-crdl</guid>
<pubDate>Fri, 16 Jan 2026 13:20:00 GMT</pubDate>
<description>Canadian Investment Regulatory Organization Trading Halt - CRDL Canada NewsWire TO...</description>
</item>
<item>
<title>Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-achieves-key-50-122700734</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-achieves-key-50-122700734</guid>
<pubDate>Tue, 13 Jan 2026 12:27:00 GMT</pubDate>
<description>Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2 2026.Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the...</description>
</item>
<item>
<title>New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/new-data-from-the-phase-ii-archer-trial-demonstrate-cardiolrxtm-improves-heart-structure-in-patients-with-acute-myocarditis-supporting-expansion-across-inflammatory-cardiac-conditions</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/new-data-from-the-phase-ii-archer-trial-demonstrate-cardiolrxtm-improves-heart-structure-in-patients-with-acute-myocarditis-supporting-expansion-across-inflammatory-cardiac-conditions</guid>
<pubDate>Mon, 01 Dec 2025 12:27:00 GMT</pubDate>
<description>Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and...</description>
</item>
<item>
<title>Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-receives-us-patent-allowance-broadly-protecting-its-heart-drugs-to-late-2040</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-receives-us-patent-allowance-broadly-protecting-its-heart-drugs-to-late-2040</guid>
<pubDate>Thu, 13 Nov 2025 12:45:00 GMT</pubDate>
<description>Once issued, this new U.S. patent covers the use of CardiolRx&#x2122; and CRD-38 for a broad rang...</description>
</item>
<item>
<title>Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-phase-ii-archer-trial-results-to-be-presented-at-the-european-society-of-cardiology-scientific-meeting-on-myocardial-and-pericardial-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-phase-ii-archer-trial-results-to-be-presented-at-the-european-society-of-cardiology-scientific-meeting-on-myocardial-and-pericardial-diseases</guid>
<pubDate>Wed, 05 Nov 2025 12:45:00 GMT</pubDate>
<description>The ESC M&amp;PD meeting brings together the world's experts working to improve the treatment of ...</description>
</item>
<item>
<title>Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-completes-usdollar114-million-financing-and-extends-cash-runway-into-q3-2027</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-completes-usdollar114-million-financing-and-extends-cash-runway-into-q3-2027</guid>
<pubDate>Tue, 21 Oct 2025 11:27:00 GMT</pubDate>
<description>MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx&#x2122; in recurrent pericardi...</description>
</item>
<item>
<title>Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-secures-usdollar11-million-financing-and-extends-cash-runway-into-q3-2027</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-secures-usdollar11-million-financing-and-extends-cash-runway-into-q3-2027</guid>
<pubDate>Fri, 17 Oct 2025 20:34:00 GMT</pubDate>
<description>MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx&#x2122; in recurrent pericardi...</description>
</item>
<item>
<title>Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-genuitys-45th-annual-growth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-genuitys-45th-annual-growth-conference</guid>
<pubDate>Mon, 11 Aug 2025 11:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) ...</description>
</item>
<item>
<title>Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrxtm-in-acute-myocarditis</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-topline-results-from-the-phase-ii-archer-trial-of-cardiolrxtm-in-acute-myocarditis</guid>
<pubDate>Wed, 06 Aug 2025 11:27:00 GMT</pubDate>
<description>Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notab...</description>
</item>
<item>
<title>Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-database-lock-for-phase-ii-archer-trial-of-cardiolrxtm-in-acute-myocarditis</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-announces-database-lock-for-phase-ii-archer-trial-of-cardiolrxtm-in-acute-myocarditis</guid>
<pubDate>Tue, 22 Jul 2025 11:27:00 GMT</pubDate>
<description>ARCHER is designed to assess the impact of CardiolRx&#x2122; on cardiac magnetic resonance imagin...</description>
</item>
<item>
<title>Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-reports-results-of-2025-annual-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/cardiol-therapeutics-inc-class-a/news/cardiol-therapeutics-reports-results-of-2025-annual-general-meeting-of-shareholders</guid>
<pubDate>Thu, 29 May 2025 11:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( ...</description>
</item>
</channel>
</rss>